JP2018512124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512124A5 JP2018512124A5 JP2017546179A JP2017546179A JP2018512124A5 JP 2018512124 A5 JP2018512124 A5 JP 2018512124A5 JP 2017546179 A JP2017546179 A JP 2017546179A JP 2017546179 A JP2017546179 A JP 2017546179A JP 2018512124 A5 JP2018512124 A5 JP 2018512124A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- independently
- linker
- amino acid
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014914 Carrier Proteins Human genes 0.000 claims 18
- 108091008324 binding proteins Proteins 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- RROLMVULBHIDTM-ZPNWYULPSA-N N[C@@H](C(C)C)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@H](CCCNC(N)=N)C(=O)O Chemical compound N[C@@H](C(C)C)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@H](CCCNC(N)=N)C(=O)O RROLMVULBHIDTM-ZPNWYULPSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 208000024883 bone remodeling disease Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 | |
| US62/128,149 | 2015-03-04 | ||
| PCT/US2016/020780 WO2016141245A1 (en) | 2015-03-04 | 2016-03-03 | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512124A JP2018512124A (ja) | 2018-05-17 |
| JP2018512124A5 true JP2018512124A5 (OSRAM) | 2019-03-28 |
| JP6745275B2 JP6745275B2 (ja) | 2020-08-26 |
Family
ID=55524479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546179A Active JP6745275B2 (ja) | 2015-03-04 | 2016-03-03 | トランスフォーミング増殖因子β１に高親和性、アビディティおよび特異性で結合する修飾ＩｇＧ抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11325970B2 (OSRAM) |
| EP (3) | EP4495137A3 (OSRAM) |
| JP (1) | JP6745275B2 (OSRAM) |
| KR (3) | KR20240076851A (OSRAM) |
| CN (1) | CN107787329B (OSRAM) |
| AR (1) | AR103840A1 (OSRAM) |
| AU (1) | AU2016226098B2 (OSRAM) |
| DK (1) | DK3265487T3 (OSRAM) |
| ES (2) | ES2927297T3 (OSRAM) |
| HR (1) | HRP20221142T1 (OSRAM) |
| HU (1) | HUE059644T2 (OSRAM) |
| IL (1) | IL254239B2 (OSRAM) |
| LT (1) | LT3265487T (OSRAM) |
| MX (1) | MX382703B (OSRAM) |
| PL (1) | PL3265487T3 (OSRAM) |
| PT (1) | PT3265487T (OSRAM) |
| RS (1) | RS63589B1 (OSRAM) |
| RU (1) | RU2728858C2 (OSRAM) |
| SG (2) | SG11201707109XA (OSRAM) |
| SI (1) | SI3265487T1 (OSRAM) |
| TW (1) | TWI733661B (OSRAM) |
| WO (1) | WO2016141245A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| JP2019509737A (ja) * | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | ＴＧＦβ１結合性免疫グロブリンおよびその使用 |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| TW202421659A (zh) | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| TWI856437B (zh) * | 2017-01-20 | 2024-09-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| CA3104274A1 (en) * | 2018-05-10 | 2019-11-14 | Mirabiologics Inc. | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
| US12252531B2 (en) | 2018-07-11 | 2025-03-18 | Scholar Rock, Inc. | Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| MXPA06011199A (es) * | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| JP2008513542A (ja) | 2004-09-22 | 2008-05-01 | ジェンザイム・コーポレイション | 免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PL1874818T3 (pl) | 2005-04-22 | 2011-09-30 | Lilly Co Eli | Przeciwciała swoiste wobec TGF-beta 1 |
| JP2009521496A (ja) | 2005-12-23 | 2009-06-04 | イーライ リリー アンド カンパニー | ＴＧＦ−β結合組成物 |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| US8048421B2 (en) | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
| MX2009003518A (es) * | 2006-10-03 | 2009-08-25 | Genzyme Corp | Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. |
| EP2313109A2 (en) | 2008-07-02 | 2011-04-27 | Emergent Product Development Seattle, LLC | Il6 immunotherapeutics |
| ES2702049T3 (es) * | 2009-04-24 | 2019-02-27 | Univ Vanderbilt | Inducción anti-TGF-beta de crecimiento óseo |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MY171135A (en) | 2011-06-03 | 2019-09-27 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| WO2014018572A2 (en) | 2012-07-23 | 2014-01-30 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| BR112015021595A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno |
| US9598486B2 (en) * | 2013-03-20 | 2017-03-21 | Genzyme Corporation | Methods for treating osteogenesis imperfecta |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 MX MX2017011252A patent/MX382703B/es unknown
- 2016-03-03 KR KR1020247016764A patent/KR20240076851A/ko active Pending
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en not_active Ceased
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 KR KR1020237024971A patent/KR102668864B1/ko active Active
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 ES ES22180865T patent/ES2994790T3/es active Active
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 EP EP24203381.9A patent/EP4495137A3/en active Pending
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 EP EP22180865.2A patent/EP4163299B1/en active Active
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active Active
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US12162933B2/en active Active
-
2024
- 2024-11-06 US US18/939,307 patent/US20250179163A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512124A5 (OSRAM) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| JP2022079549A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| JP2020515508A5 (OSRAM) | ||
| JP2016525551A5 (OSRAM) | ||
| JP2020536109A5 (OSRAM) | ||
| FI3922645T3 (fi) | Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| JP2019535763A5 (OSRAM) | ||
| JP2018502572A5 (OSRAM) | ||
| JP2019501883A5 (OSRAM) | ||
| JP2014518615A5 (OSRAM) | ||
| JP2016529229A5 (OSRAM) | ||
| JP2019506841A5 (OSRAM) | ||
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2017529067A5 (OSRAM) | ||
| CN107108737B (zh) | c-met特异性人抗体及其制备方法 | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof |